Genetic Technologies Ltd (ASX:GTG) Share Price

Company Profile

Business description
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
Contact
60-66 Hanover Street
Fitzroy
MelbourneVIC3065
AUS
T: +61 384127000
https://www.gtglabs.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2025
Employees
60

Recommended

Shares drop 17% after guidance is revised but we still see value.

Shane Ponraj | 09 January 2025

Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.

Joseph Taylor | 09 January 2025

These undervalued stocks with reliable dividends are worth considering.

Susan Dziubinski | 08 January 2025

Index	Last price	Change	% Change
All Ordinaries	8,543.70	34.10	-0.40%
CAC 40	7,431.04	59.24	-0.79%
DAX 40	20,214.79	102.31	-0.50%
Dow JONES (US)	41,938.45	696.75	-1.63%
FTSE 100	8,248.49	71.20	-0.86%
HKSE	19,064.29	176.60	-0.92%
NASDAQ	19,161.63	317.25	-1.63%
Nikkei 225	39,190.40	414.69	-1.05%
NZX 50 Index	12,895.98	47.76	-0.37%
S&P 500	5,827.04	91.21	-1.54%
S&P/ASX 200	8,294.10	35.10	-0.42%
SSE Composite Index	3,168.52	42.87	-1.33%